Total Payments
$2,725
2024 Payments
$82.50
Companies
6
Transactions
49
Medicare Patients
306
Medicare Billing
$44,747
Payment Breakdown by Category
Research$1,108 (40.7%)
Food & Beverage$945.31 (34.7%)
Travel$642.50 (23.6%)
Education$28.48 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,108 | 15 | 40.7% |
| Food and Beverage | $945.31 | 28 | 34.7% |
| Travel and Lodging | $642.50 | 5 | 23.6% |
| Education | $28.48 | 1 | 1.0% |
Payments by Type
General
$1,616
34 transactions
Research
$1,108
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,401 | 26 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $945.28 | 9 | $0 (2020) |
| ViiV Healthcare Company | $310.40 | 11 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $28.48 | 1 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $24.75 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $14.17 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $82.50 | 2 | ViiV Healthcare Company ($82.50) |
| 2023 | $73.61 | 3 | ViiV Healthcare Company ($48.86) |
| 2022 | $29.28 | 1 | ViiV Healthcare Company ($29.28) |
| 2021 | $130.48 | 5 | ViiV Healthcare Company ($102.00) |
| 2020 | $1,016 | 12 | Merck Sharp & Dohme Corporation ($945.28) |
| 2019 | $1,108 | 15 | Gilead Sciences, Inc. ($1,108) |
| 2018 | $170.34 | 7 | Gilead Sciences, Inc. ($156.17) |
| 2017 | $114.31 | 4 | Gilead Sciences Inc ($114.31) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/29/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: HIV | ||||||
| 03/27/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $54.25 | General |
| 11/15/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $28.26 | General |
| 09/20/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: HIV | ||||||
| 03/27/2023 | Janssen Scientific Affairs, LLC | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 02/09/2022 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: HIV | ||||||
| 12/13/2021 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 10/13/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: HIV | ||||||
| 06/23/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: HIV | ||||||
| 03/24/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.32 | General |
| Category: HIV | ||||||
| 02/17/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: HIV | ||||||
| 12/16/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: HIV | ||||||
| 09/08/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: HIV | ||||||
| 08/26/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.73 | General |
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $66.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $48.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $39.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $231.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $226.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $149.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | Cash or cash equivalent | $21.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/13/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $95.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $301.96 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $213.23 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,006 | 12 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 74 | 139 | $57,559 | $12,003 |
| 2022 | 4 | 77 | 137 | $56,869 | $12,253 |
| 2021 | 4 | 71 | 113 | $43,821 | $11,031 |
| 2020 | 5 | 84 | 109 | $35,125 | $9,459 |
Total Patients
306
Total Services
498
Medicare Billing
$44,747
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 71 | $20,161 | $4,675 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 27 | $18,873 | $3,106 | 16.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 23 | $8,993 | $2,278 | 25.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $9,532 | $1,945 | 20.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 84 | $32,160 | $7,047 | 21.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $7,864 | $1,945 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 16 | $11,014 | $1,800 | 16.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 25 | $5,831 | $1,460 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 66 | $21,852 | $5,671 | 26.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $9,510 | $2,498 | 26.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 15 | $8,600 | $1,846 | 21.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 17 | $3,859 | $1,016 | 26.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 33 | 56 | $18,144 | $4,914 | 27.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $10,064 | $2,704 | 26.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 13 | $4,599 | $753.80 | 16.4% |
| 90682 | Vaccine for influenza for injection into muscle | Office | 2020 | 12 | 12 | $709.20 | $709.20 | 100.0% |
| 99451 | Telephone or internet assessment and management service provided by consultative physician with written report, 5 minutes or more of medical consultative discussion and review | Facility | 2020 | 12 | 12 | $1,609 | $378.36 | 23.5% |
About Dr. Sarah Waldman, M.D
Dr. Sarah Waldman, M.D is a Infectious Disease healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2011. The National Provider Identifier (NPI) number assigned to this provider is 1376832550.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarah Waldman, M.D has received a total of $2,725 in payments from pharmaceutical and medical device companies, with $82.50 received in 2024. These payments were reported across 49 transactions from 6 companies. The most common payment nature is "" ($1,108).
As a Medicare-enrolled provider, Waldman has provided services to 306 Medicare beneficiaries, totaling 498 services with total Medicare billing of $44,747. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Sacramento, CA
- Active Since 03/29/2011
- Last Updated 05/02/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1376832550
Products in Payments
- MK-8591A (Drug) $945.28
- Biktarvy (Drug) $121.87
- DOVATO (Drug) $119.66
- CABENUVA (Biological) $58.35
- APRETUDE (Biological) $49.88
- SYMTUZA (Drug) $24.75
- PREZCOBIX (Drug) $14.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sacramento
Claire Pomeroy, M.d., M.b.a, M.D., M.B.A
Infectious Disease — Payments: $2.5M
Infectious Disease $2.5M
Dr. David Asmuth, M.d, M.D
Infectious Disease — Payments: $424,974
Infectious Disease $424,974
Stuart Cohen, M.d, M.D
Infectious Disease — Payments: $15,711
Infectious Disease $15,711
Daniel Ikeda, M.d, M.D
Infectious Disease — Payments: $8,220
Infectious Disease $8,220
Dr. Richard Pollard, Md, MD
Infectious Disease — Payments: $4,763
Infectious Disease $4,763
Vinod Trivedi, Md, MD
Infectious Disease — Payments: $4,508
Infectious Disease $4,508